BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25615245)

  • 1. What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?
    Mirheydar HS; Banapour P; Massoudi R; Palazzi KL; Jabaji R; Reid EG; Millard FE; Kane CJ; Sur RL
    Int Braz J Urol; 2014; 40(6):772-80. PubMed ID: 25615245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in 24-h urine composition between nephrolithiasis patients with and without diabetes mellitus.
    Hartman C; Friedlander JI; Moreira DM; Elsamra SE; Smith AD; Okeke Z
    BJU Int; 2015 Apr; 115(4):619-24. PubMed ID: 24823472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure.
    Faggiano A; Pivonello R; Melis D; Filippella M; Di Somma C; Petretta M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2003 May; 88(5):2076-80. PubMed ID: 12727957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes increases the risk for uric acid stones.
    Daudon M; Traxer O; Conort P; Lacour B; Jungers P
    J Am Soc Nephrol; 2006 Jul; 17(7):2026-33. PubMed ID: 16775030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-uric acid nephrolithiasis.
    Coe FL
    Arch Intern Med; 1978 Jul; 138(7):1090-3. PubMed ID: 666467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia and kidney stone risk.
    Torricelli FC; De SK; Gebreselassie S; Li I; Sarkissian C; Monga M
    J Urol; 2014 Mar; 191(3):667-72. PubMed ID: 24055417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and medical management of kidney stones in children.
    Tasian GE; Copelovitch L
    J Urol; 2014 Nov; 192(5):1329-36. PubMed ID: 24960469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Functional evaluation in patients with kidney calculi].
    Stojimirović B
    Srp Arh Celok Lek; 1998; 126(9-10):394-8. PubMed ID: 9863414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers.
    Eisner BH; Porten SP; Bechis SK; Stoller ML
    J Urol; 2010 Jun; 183(6):2244-8. PubMed ID: 20400141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome and urinary stone composition: what factors matter most?
    Kadlec AO; Greco K; Fridirici ZC; Hart ST; Vellos T; Turk TM
    Urology; 2012 Oct; 80(4):805-10. PubMed ID: 22795374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up.
    Taylor EN; Stampfer MJ; Curhan GC
    J Am Soc Nephrol; 2004 Dec; 15(12):3225-32. PubMed ID: 15579526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and prevention of uric acid stones].
    Ferrari P; Bonny O
    Ther Umsch; 2004 Sep; 61(9):571-4. PubMed ID: 15493118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrolithiasis in Israel: Epidemiological Characteristics of Return Patients in a Tertiary Care Center.
    Abu-Ghanem Y; Kleinmann N; Winkler HZ; Zilberman DE
    Isr Med Assoc J; 2016 Dec; 18(12):725-728. PubMed ID: 28457074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study.
    Kim S; Chang Y; Yun KE; Jung HS; Lee SJ; Shin H; Ryu S
    Am J Kidney Dis; 2017 Aug; 70(2):173-181. PubMed ID: 28410765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of metabolic syndrome with urinary stone composition.
    Cho ST; Jung SI; Myung SC; Kim TH
    Int J Urol; 2013 Feb; 20(2):208-13. PubMed ID: 23020870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of visceral fat area and other metabolic parameters on stone composition in patients undergoing percutaneous nephrolithotomy.
    Zhou T; Watts K; Agalliu I; DiVito J; Hoenig DM
    J Urol; 2013 Oct; 190(4):1416-20. PubMed ID: 23685097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 100% uric acid stone formers: what makes them different?
    Reichard C; Gill BC; Sarkissian C; De S; Monga M
    Urology; 2015 Feb; 85(2):296-8. PubMed ID: 25623669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body size and 24-hour urine composition.
    Taylor EN; Curhan GC
    Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.